US2022105131A1PendingUtilityA1

Pharmaceutical compositions

82
Assignee: VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTDPriority: Nov 16, 2007Filed: Dec 16, 2021Published: Apr 7, 2022
Est. expiryNov 16, 2027(~1.3 yrs left)· nominal 20-yr term from priority
Inventors:Ludwig Daniel WeibelErik Philipp
A61K 47/26A61K 33/26A61K 9/2059A61K 9/2866A61P 3/12A61K 9/205A61K 9/009A61P 7/00A61P 5/18A61K 9/1623A61K 9/0056A61K 47/02A61K 9/70A61K 9/2027A61K 9/2018A61P 19/08A61K 9/1635A61K 9/1652A61P 7/08A61P 13/00A61K 9/0053A61P 3/00A61K 9/2095A61P 13/12
82
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Pharmaceutical compositions for oral administration, in particular administration as an oral delivery system to be swallowed directly or capable of disintegration in the oral cavity, comprising iron oxy-hydroxide in high loading.

Claims

exact text as granted — not AI-modified
1 - 25 . (canceled) 
     
     
         26 . A stabilized iron oxy-hydroxide premixture comprising iron oxy-hydroxide, saccharose, native starch, pregelatinized starch, and optionally water,
 wherein the iron oxy-hydroxide is stabilized by at least saccharose, native starch, and/or pregelatinized starch, and   wherein the iron oxy-hydroxide is essentially non-bioabsorbable.   
     
     
         27 . The stabilized iron oxy-hydroxide premixture according to  claim 26 , wherein native starch and pregelatinized starch are present in a ratio (native:pregelatinized) in the range of 10:1 to 0.5:1. 
     
     
         28 . The stabilized iron oxy-hydroxide premixture according to  claim 26 , wherein native starch and pregelatinized starch are present in a ratio (native:pregelatinized) in the range of 3:1 to 0.5:1. 
     
     
         29 . A pharmaceutical composition of iron oxy-hydroxide for oral administration, comprising the premixture according to  claim 26 . 
     
     
         30 . A pharmaceutical composition of iron oxy-hydroxide for oral administration, comprising the premixture according to  claim 27 . 
     
     
         31 . A pharmaceutical composition of iron oxy-hydroxide for oral administration, comprising the premixture according to  claim 28 . 
     
     
         32 . The pharmaceutical composition according to  claim 29 , wherein the iron oxy-hydroxide is present in the amount of 10 to 80% (w/w) expressed in relation to the total weight of the composition. 
     
     
         33 . The pharmaceutical composition according to  claim 30 , wherein the iron oxy-hydroxide is present in the amount of 10 to 80% (w/w) expressed in relation to the total weight of the composition. 
     
     
         34 . The pharmaceutical composition according to  claim 31 , wherein the iron oxy-hydroxide is present in the amount of 10 to 80% (w/w) expressed in relation to the total weight of the composition. 
     
     
         35 . The pharmaceutical composition according to  claim 32 , wherein the total amount of the stabilized iron oxy-hydroxide premixture is greater than 50% (w/w) expressed relative to the total weight of the composition. 
     
     
         36 . The pharmaceutical composition according to  claim 33 , wherein the total amount of the stabilized iron oxy-hydroxide premixture is greater than 50% (w/w) expressed relative to the total weight of the composition. 
     
     
         37 . The pharmaceutical composition according to  claim 34 , wherein the total amount of the stabilized iron oxy-hydroxide premixture is greater than 50% (w/w) expressed relative to the total weight of the composition. 
     
     
         38 . The pharmaceutical composition according to  claim 32 , wherein the total amount of the stabilized iron oxy-hydroxide premixture is greater than 70% (w/w) expressed relative to the total weight of the composition. 
     
     
         39 . The pharmaceutical composition according to  claim 33 , wherein the total amount of the stabilized iron oxy-hydroxide premixture is greater than 70% (w/w) expressed relative to the total weight of the composition. 
     
     
         40 . The pharmaceutical composition according to  claim 34 , wherein the total amount of the stabilized iron oxy-hydroxide premixture is greater than 70% (w/w) expressed relative to the total weight of the composition. 
     
     
         41 . The pharmaceutical composition according to  claim 35 , wherein the pharmaceutical composition is in a dosage form chosen from tablets, pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         42 . The pharmaceutical composition according to  claim 36 , wherein the pharmaceutical composition is in a dosage form chosen from tablets, pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         43 . The pharmaceutical composition according to  claim 37 , wherein the pharmaceutical composition is in a dosage form chosen from tablets, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         44 . The pharmaceutical composition according to  claim 38 , wherein the pharmaceutical composition is in a dosage form chosen from tablets, pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         45 . The pharmaceutical composition according to  claim 39 , wherein the pharmaceutical composition is in a dosage form chosen from tablets, pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         46 . The pharmaceutical composition according to  claim 40 , wherein the pharmaceutical composition is in a dosage form chosen from tablets, pills, dry powders, granules, sachets containing granules, and stick packs containing granules. 
     
     
         47 . The pharmaceutical composition according to  claim 32 , wherein the pharmaceutical composition is in a dosage form chosen from granules and dry powders. 
     
     
         48 . The pharmaceutical composition according to  claim 33 , wherein the pharmaceutical composition is in a dosage form chosen from granules and dry powders. 
     
     
         49 . The pharmaceutical composition according to  claim 34 , wherein the pharmaceutical composition is in a dosage form chosen from granules and dry powders. 
     
     
         50 . The pharmaceutical composition according to  claim 32 , wherein the iron oxy-hydroxide comprises beta iron oxy-hydroxide. 
     
     
         51 . The pharmaceutical composition according to  claim 33 , wherein the iron oxy-hydroxide comprises beta iron oxy-hydroxide. 
     
     
         52 . The pharmaceutical composition according to  claim 34 , wherein the iron oxy-hydroxide comprises beta iron oxy-hydroxide. 
     
     
         53 . The pharmaceutical composition according to  claim 47 , wherein the iron oxy-hydroxide comprises beta iron oxy-hydroxide. 
     
     
         54 . The pharmaceutical composition according to  claim 48 , wherein the iron oxy-hydroxide comprises beta iron oxy-hydroxide. 
     
     
         55 . The pharmaceutical composition according to  claim 49 , wherein the iron oxy-hydroxide comprises beta iron oxy-hydroxide.

Join the waitlist — get patent alerts

Track US2022105131A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.